Page 156 - CW E-Magazine (19-11-2024)

Top Stories Pharmaceuticals

FINANCIAL PERFORMANCE PHARMA CONGREGATION

Asian Paints’ Q2 profi t slides by over 43% Dhaka to host Asia Pharma Expo 2025 in February

Asian Paints has reported a 43.71 Asian Paints’ total expenses were impact of it should fl ow through Ahmedabad-based GPE Expo Pvt. turnout of over 12,000 for the show.
percent decline in consolidated net at Rs. 7,093.03-crore in the September only in the second half of the year, Ltd. In association with Bangladesh Bangladesh’s pharmaceutical sector
profi t to Rs. 693.66-crore for the second quarter, up 1 percent. Its total income, he added. Association of Pharmaceutical Indus- has emerged as a key contributor to
quarter ended September 30, 2024, which includes revenue from other tries (BAPI) is organising the 16th both its domestic economy and inter-
impacted by soft-demand conditions, sources, was down 5.12 percent at “We expect margins to recover in edition of Asia Pharma Expo 2025 & national trade. With over 300 local
material price infl ation and a decline Rs. 8,201.09-crore during the second the coming quarters on the back of anti- Asia Lab Expo 2025, at the BBCFEC, manufacturers supplying 98% of do-
in decorative & coatings business in quarter of the current fi scal year. cipated softening in material prices Purbachal, Dhaka, Bangladesh, from mestic medicinal needs, the industry
the domestic market. coupled with price increases imple- February 12-14, 2025. has fl ourished in recent years. Valued
Commenting on the results, Mana- mented in the last few months,” said at approximately $3-bn, Bangladesh’s
The company had logged a net profi t ging Director & CEO Mr. Amit Syngle Mr. Syngle. The leading pharmaceutical trade pharmaceutical industry is rapidly ex-
of Rs. 1,232.39-crore during the July- said, “The paint industry faced a sub- platform will host over 800 compa- panding, with exports reaching more
September period a year ago, according dued demand environment during the In its international business, Asian nies from around 32 countries show- than 150 countries. By 2025, the mar-
to a regulatory fi ling by Asian Paints. quarter. Domestic decorative coatings Paints’ sales decreased 0.7 percent to ing solutions across pharmaceutical ket size is expected to surpass $6-bn,
segment volumes declined marginally Rs. 769.5-crore on the back of macro- processing, packaging, ingredients ments, cleanroom technologies, and and exports are projected to exceed
Its revenue from operations was while overall domestic coatings reve- economic and currency devaluation (APIs, excipients, etc), lab instru- others. The organisers expect a visitor $450-mn.
down 5.3 percent to Rs. 8,027.54-crore nue declined by 5.5 percent for the in Ethiopia, Egypt, and Bangladesh.
in the September quarter. In the year-ago quarter impacted by muted consumer However, in constant currency terms, NEW OPPORTUNITIES
period, it stood at Rs. 8,478.57-crore. sentiments and extended rains and “sales increased 8.7 percent. Profi t Lupin aims to be among fi rst to launch generic
“On the margin front, soft-demand con- fl oods in some parts of the country”. before tax (PBT) in Q2 FY25 was a loss
ditions, product mix, and material price of Rs. 21.5-crore as against profi t of GLP-1 products
infl ation affected margins in Q2,” Asian Though the company made price Rs. 40.4-crore in the corresponding
Paints said in its earning statement. increases during the quarter, the full period of the previous year”.
Mumbai-based drugmaker, Lupin, The company aims to be part of the The company has in-house capabilities
India’s energy effi ciency market size to hit $20-bn is aiming to be part of the fi rst wave fi rst wave of generics on GLP-1 pro- to develop and manufacture the pro-
of generic drugmakers to make GLP-1 ducts and hopes to launch the fi rst duct, he said, adding that a clear strategy
in 2024: IEA (glucagon-like peptide-1) receptor of these in 2026, Lupin’s Managing would play out next year.
agonists products, used to treat type II Director Mr. Nilesh Gupta told analysts
diabetes and obesity. This segment recently. The regions opening up for GLP-1
India’s energy effi ciency efforts incentives for electric mobility in the of products includes semaglutide, the launches, following patent expiry,
have gained momentum in 2024, with transport sector, are pivotal. internationally popular weight-loss Lupin’s strategy in India and other include India, South Africa, Latin
a substantial improvement being made product from Novo Nordisk sold as emerging markets would be a mix of America, Philippines and parts of
in recent years, according to a report by Enhanced building codes and ex- ‘Ozempic’ — poised to go off patent developing the product internally and Eastern Europe, said Ms. Vinita Gupta,
Paris-based energy think-tank, Inter- panded labelling for appliances have protection in some markets in 2026. licensing it, as the case may be, he said. Lupin’s Chief Executive Offi cer.
national Energy Agency (IEA). broadened effi ciency efforts, with state-
owned Energy Effi ciency Services Ltd. REGULATORY ACTION
Energy efficiency investments (EESL) playing a central role in market
across sectors touched $18-bn in 2023, expansion, it said. US-FDA classifi es Biocon Biologics’ Bengaluru
double that from four years prior, could see a 3 percent annual improve-
and are projected to approach $20-bn ment, rising to over 4 percent with Programmes such as Faster Adoption plant as ‘VAI’
in 2024. pledged commitments. and Manufacturing of Electric Vehicles
(FAME) and the Production Linked In- The United States Food and Drug agency during July 15-26, 2024. “The company informed. ‘VAI’ means objec-
Following an annual primary energy India’s energy effi ciency strategy centive (PLI) scheme provide tax bene- Administration (FDA) has issued “volun- inspection scope had included six sep- tionable conditions or practices were
intensity improvement rate of under includes a comprehensive Standards fi ts and incentives for local manufactur- tary action indicated” or VAI tag to arate biologics manufacturing units found, but they are not severe enough
1 percent in 2021 and 2022, India has and Labelling programme covering 39 ing, critical in scaling effi ciency efforts. the manufacturing facilities of Biocon comprising of four drug substance and to attract any administrative or regula-
accelerated to a projected 2.5 percent appliances - 16 with mandatory stan- Though public funding is essential, do- Biologics in Bengaluru. This update is two drug product manufacturing plants tory action. The company can fi x the
improvement in 2024, matching the dards and 23 voluntary. Key initia- mestic and international private invest- related to the combined cGMP inspec- as well as fi ve analytical quality con- observed loopholes without the watch-
2010-2019 average. Under the IEA’s tives such as the Perform, Achieve, and ments and energy service companies tion and pre-licensing inspection (PLI), trol laboratories, four microbiology dog’s intervention and operations can
‘Stated Policies Scenario’, the country Trade (PAT) scheme for industry, and (ESCOs) are increasingly vital, it said. which was conducted by the regulatory laboratories, and two warehouses,” the carry on as usual.

156 Chemical Weekly November 19, 2024 Chemical Weekly November 19, 2024 157

Contents Index to Advertisers Index to Products Advertised